MedTrace Logo

Oral Progesterone for Prevention of Miscarriage in Threatened Abortion

NCT04788108 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-08-30

No results posted yet for this study

Summary

This study evaluates the effectiveness of oral dydrogesterone in preventing miscarriage in threatened abortion. Half of participants will receive oral dydrogesterone, while the other half will receive oral placebo.

Conditions

  • Threatened Abortion

Interventions

DRUG

Dydrogesterone

Dydrogesterone tablet

DRUG

Placebo

Placebo tablet

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Vorapong Phupong, M.D. · Chulalongkorn University, Faculty of Medicine, Department of Obstetrics and Gynecology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788108 on ClinicalTrials.gov